Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study

Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study

BACKGROUND: Chronic myeloid leukemia (CML), a myeloproliferative neoplasm caused by genetic abnormality resulted in BCR-ABL1 fusion gene, leading to constitutive tyrosine kinase activity. Despite improved treatment outcomes of tyrosine kinase inhibitors (TKIs), resistance to these agents due to muta...

Full description

Saved in:
Bibliographic Details
Main Authors: Alaa Fadhil Alwan, Mushtaq M. Khazeem, Zaidoon Jamal Tuama
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-01-01
Series:Iraqi Journal of Hematology
Subjects:
bcr-abl level
bosutinib
chronic myeloid leukemia
tyrosine kinase inhibitors
Online Access:https://journals.lww.com/10.4103/ijh.ijh_1_25
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items